Sagimet's Denifanstat Shows Sustained Efficacy in Acne Trials, U.S. Phase 3 Underway
Event summary
- Sagimet to present 52-week Phase 3 data for denifanstat in acne at Fall Clinical Dermatology Conference, showing 57% IGA success and 72% lesion reduction.
- U.S. Phase 3 AURORA trial for denifanstat now screening patients with IRB approvals in place.
- Ascletis' NDA submission for denifanstat in China accepted by NMPA in December 2025.
- Denifanstat demonstrated sustained efficacy through 52 weeks in open-label extension trial.
The big picture
Sagimet's positive Phase 3 data for denifanstat reinforces the potential of FASN inhibition as a novel oral treatment for moderate to severe acne. The U.S. Phase 3 trial initiation marks a critical step in Sagimet's strategy to expand denifanstat's global reach, following Ascletis' regulatory progress in China. The dermatology market, particularly for acne treatments, remains underserved for long-term solutions, making denifanstat's sustained efficacy a key differentiator.
What we're watching
- Regulatory Pathway
- Whether Ascletis can secure NMPA approval for denifanstat in China and its potential impact on Sagimet's global strategy.
- Clinical Execution
- The pace at which Sagimet can enroll and complete the U.S. Phase 3 AURORA trial, particularly among adolescent patients.
- Market Differentiation
- How denifanstat's long-term efficacy data will position it against existing acne treatments in a competitive dermatology market.
